Our research

The ability of cannabinoids such as cannabidiol (CBD) to reduce anxiety, prevent seizures and reduce psychotic behaviour may be relevant in the treatment of addiction to alcohol and other drugs

We are conducting research to explore the effects of regular cannabis use in the community

As medical cannabis becomes more readily available, it is imperative that we answer questions around the risks. Our research is contributing to the ongoing policy debate regarding issues such as safety, impairment and detection when driving.

Katelyn Lambert suffers from Dravet syndrome, a severe form of childhood epilepsy unresponsive to current anticonvulsant drugs. We’re developing cannabinoid medicines to reduce seizures, mortality and intellectual disability.

Our medicinal chemistry team are synthesising innovative libraries of cannabinoid molecules to discover and develop new clinical candidates with improved therapeutic properties.

The Lambert Initiative is researching the application of phytocannabinoids to assist in the treatment and management of chronic and neuropathic pain.

We have conducted a variety of surveys that have shed light on various aspects of medical cannabis in Australia, covering both general practitioners and patients.

We see great potential for clinical trials of cannabinoids for mental health disorders, thanks to its ability to reduce anxiety and psychosis. The precise mechanism by which the endocannabinoid system modulates anxiety and depression is not fully understood, so further research is already underway.

With computational modelling, we can simulate the molecular interactions between cannabinoids and receptors to gain insight into their physiological activity and expand their therapeutic applications.

Our research aims to better understand the cannabis plant, its compounds and potential therapeutic value. This requires an investigation of how our endocannabinoid system works, how it interacts with other biological systems, and how it responds to interventions.

We are researching cannabinoids to uncover the potential of medical cannabis and PTSD.

Insomnia is a very common disorder that can affect up to 50% of the general population at any given time. Anecdotally, cannabis is frequently reported to promote sleep, however, there are very few studies investigating how cannabis affects the brain during sleep in people with insomnia.

There is already early evidence to support the successful treatment of Tourette syndrome with cannabinoids. Medicinal cannabis has the potential to be a treatment option that avoids aggressive side effects and greatly improves quality of life.